These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 10878512)

  • 21. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.
    Romano M; Vacante M; Cristaldi E; Colonna V; Gargante MP; Cammalleri L; Malaguarnera M
    Dig Dis Sci; 2008 Apr; 53(4):1114-21. PubMed ID: 17939042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C.
    Maiellaro PA; Cozzolongo R; Marino P
    Curr Pharm Des; 2004; 10(17):2101-9. PubMed ID: 15279549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards predicting the therapeutic response in patients with hepatitis C.
    Féray C
    Aliment Pharmacol Ther; 2010 Jan; 31(2):339-40; author reply 340-1. PubMed ID: 20078498
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term interferon-alpha therapy does not affect sex hormones in males with chronic hepatitis C.
    Piazza M; Tosone G; Borgia G; Orlando R; Fenzi G; Vitale M; Bloise A; Mariano A; Macchia V
    J Interferon Cytokine Res; 1997 Sep; 17(9):525-9. PubMed ID: 9335429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microarrays and prediction of interferon response in chronic hepatitis C: not yet ready for prime time.
    Yeung E; Chung RT
    Clin Gastroenterol Hepatol; 2005 Dec; 3(12):1192-4. PubMed ID: 16361043
    [No Abstract]   [Full Text] [Related]  

  • 26. Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay.
    Morisco F; Verde V; Fogliano V; Ritieni A; Marmo R; De Luise G; Tuccillo C; Caporaso N
    Free Radic Res; 2004 Jun; 38(6):573-80. PubMed ID: 15346648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of 6-month intermittent administration of natural human interferon-alpha against non-A non-B chronic hepatitis.
    Sata M; Atono Y; Nakano H; Morita Y; Hino T; Ide T; Yano Y; Noguchi S; Tokeshi S; Ono K
    Kansenshogaku Zasshi; 1992 Jun; 66(6):667-78. PubMed ID: 1431348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Parameters of humoral immunity in patients with breast carcinoma during therapy with leukocyte interferon].
    Tomin R; Juranić Z; Spuzić I; Culafić M
    Glas Srp Akad Nauka Med; 1991; (41):97-104. PubMed ID: 1916452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Can we advance the diagnosis of the sustained virological response to 12 weeks after finishing HVC treatment?].
    Mira JA; Macías J
    Enferm Infecc Microbiol Clin; 2012 Jan; 30(1):1-2. PubMed ID: 22197276
    [No Abstract]   [Full Text] [Related]  

  • 30. Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C.
    Wedemeyer H; Ockenga J; Frank H; Tillmann HL; Schuler A; Caselitz M; Gebel M; Trautwein C; Manns MP
    Hepatogastroenterology; 1998; 45(22):1062-8. PubMed ID: 9756007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erratum for: Evaluating GPT-4V (GPT-4 with Vision) on Detection of Radiologic Findings on Chest Radiographs.
    Zhou Y; Ong H; Kennedy P; Wu CC; Kazam J; Hentel K; Flanders A; Shih G; Peng Y
    Radiology; 2024 May; 311(2):e249016. PubMed ID: 38805735
    [No Abstract]   [Full Text] [Related]  

  • 32. Author Correction: A pilot study on the efficacy of GPT-4 in providing orthopedic treatment recommendations from MRI reports.
    Truhn D; Weber CD; Braun BJ; Bressem K; Kather JN; Kuhl C; Nebelung S
    Sci Rep; 2024 Mar; 14(1):5431. PubMed ID: 38443449
    [No Abstract]   [Full Text] [Related]  

  • 33. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.
    Pol S; Nalpas B; Bourlière M; Couzigou P; Tran A; Abergel A; Zarski JP; Berthelot P; Bréchot C
    Hepatology; 2000 Jun; 31(6):1338-44. PubMed ID: 10827161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C].
    Olaso V; Córdoba J; Lòpez Viedma B; Siles MS; Molina JM; Prieto M; Baum I; Gobernado M; Berenguer J
    Rev Esp Quimioter; 1999 Sep; 12(3):220-8. PubMed ID: 10878512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
    Olaso V; Córdoba J; Molina JM; López B; Siles MS; Monte E; Calvo F; Bau I; Beltrán B; Martínez B; Gobernado M
    Rev Esp Quimioter; 2002 Dec; 15(4):366-73. PubMed ID: 12587043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.